Take a look at our previous reports:

16. Research and development incentives receivables

The table below illustrates the R&D incentives receivables related captions in the balance sheet as at 31 December 2022, and 2021.

 

31 December

(thousands of €)

2022

2021

Non-current R&D incentives receivables

119,941

127,186

Current R&D incentives receivables

26,126

16,827

Total R&D incentives receivables

146,067

144,013

The increase in R&D incentives receivables is explained by additional R&D incentives reported in 2022 for €28.7 million (€11.4 million related to French incentives and €17.3 million related to Belgian incentives), by the release of discounting profit of €0.1 million, partly offset by the setup of tax provisions in France and Belgium for respectively €0.2 million and €0.2 million and decreased by the payments received in 2022 related to French and Belgian incentives amounting to respectively €10.2 million and €16.1 million. The R&D tax incentives receivables are future expected refunds or tax deductions resulting from tax incentives on research and development expenses in France and Belgium. Non-current R&D incentives receivables are reported at their net present value and are therefore discounted over the period until maturity date.

The table below provides detailed information on the maturity of the non-current R&D incentives receivables reported in our balance sheet on 31 December 2022.

 

31 December 2022

 

 

Maturity date

 

(thousands of €)

2024

2025

2026

2027

2028 –
2030

Total

French non-current R&D incentives receivables - discounted value

11,713

11,495

11,207

 

 

34,415

Belgian non-current R&D incentives receivables - discounted value

16,805

18,604

19,443

13,908

16,767

85,526

Total non-current R&D incentives receivables - discounted value

28,518

30,099

30,650

13,908

16,767

119,941

Development
All activities required to bring a new drug to the market. This includes preclinical and clinical development research, chemical and pharmaceutical development and regulatory filings of product candidates